Low-density lipoprotein apheresis therapy for steroid-and cyclosporine-resistant idiopathic membranous nephropathy

Internal Medicine

Volumn 51, Issue 18, 2012, Pages 2597-2602

  Sato, Yoshinori ^a,c   Tsunoda, Shinichiro ^b,c   Nozue, Tsuyoshi ^c   Pan, Qinya ^c   Wakasugi, Harue ^c   Yoshimura, Ashio ^a  

^a SHOWA UNIVERSITY FUJIGAOKA HOSPITAL   (Japan)

^b Hyogo College of Medicine   (Japan)

^c Yokohama Sakae Kyosai Hospital   (Japan)

Author keywords

Cyclosporine; Idiopathic membranous nephropathy(IMN); LDL apheresis; Nephrotic syndrome (NS)

Indexed keywords

ATORVASTATIN; CYCLOSPORIN; IMMUNOGLOBULIN G; LOW DENSITY LIPOPROTEIN; METHYLPREDNISOLONE; PREDNISOLONE; STEROID;

ABDOMINAL SURGERY; ADULT; AGED; APHERESIS; ARTICLE; CASE REPORT; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; EDEMA; FEMALE; GLOMERULOSCLEROSIS; HEMODIALYSIS; HUMAN; HUMAN TISSUE; HYPOALBUMINEMIA; HYPOPROTEINEMIA; IMMUNOFLUORESCENCE MICROSCOPY; IMMUNOSUPPRESSIVE TREATMENT; INGUINAL HERNIA; KIDNEY BIOPSY; KIDNEY FAILURE; LOW DRUG DOSE; MALE; MEMBRANOUS GLOMERULONEPHRITIS; MULTIPLE CYCLE TREATMENT; NEPHROTIC SYNDROME; PROTEIN URINE LEVEL; PROTEINURIA; REMISSION;

ADULT; AGED; BLOOD COMPONENT REMOVAL; CYCLOSPORINE; DRUG RESISTANCE; FEMALE; GLOMERULONEPHRITIS, MEMBRANOUS; HUMANS; LIPOPROTEINS, LDL; MALE; RECURRENCE; STEROIDS; TREATMENT OUTCOME; WATER-ELECTROLYTE BALANCE;

EID: 84867859394     PISSN: 09182918     EISSN: 13497235     Source Type: Journal    
DOI: 10.2169/internalmedicine.51.7204     Document Type: Article

References (15)

1. Fervenza FC, Sethi S, Specks U. Idiopathic membranous nephropathy: Diagnosis and treatment. Clin J Am Soc Nephrol 3: 905-919, 2008.
2. Polanco N, Gutierrez E, Covarsi A, et al. Spontaneous remission of nephrotic syndrome in idiopathic membranous nephropathy. J Am Soc Nephrol 21: 697-704, 2010.
3. Cattran DC, Appel GB, Hebert LA, et al. Cyclosporine in patients with steroid-resistant membranous nephropathy: a randomized trial. Kidney Int 59: 1484-1490, 2001.
4. Pei Y, Cattran D, Greenwood C. Predicting chronic renal insufficiency in idiopathic membranous glomerulonephritis. Kidney Int 42: 960-966, 1992.
5. Cattran DC, Pei Y, Greenwood CM, Ponticelli C, Passerini P, Honkanen E. Validation of a predictive model of idiopathic membranous nephropathy: its clinical and research implications. KidneyInt 51: 901-907, 1997.
6. Muso E, Yashiro M, Matsushima M, Yoshida H, Sawanishi K,Sasayama S. Does LDL-apheresis in steroid-resistant nephritic syndrome affect prognosis? Nephrol Dial Transplant 9: 257-264,1994.
7. Hattori M, Chikamoto H, Akioka Y, et al. A combined low-density lipoprotein apheresis and prednisone therapy for steroid-resistant primary focal segmental glomerulosclerosis in children. Am J Kidney Dis 42: 1121-1130, 2003.
8. Kobayashi T, Ando Y, Umino T, et al. Complete remission of minimal-change nephrotic syndrome induced by apheresis monotherapy. Clin Nephrol 65: 423-426, 2006.
9. Petrichenko I, Daret D, Larrue J, Shakhov Y. Effect of VLDL on the inhibition of arachidonic acid transformation by dexamethasone in cultured smooth muscle cells. Biochim Biophys Acta 1166: 183-187, 1993.
10. de Groen PC. Cyclosporine, low-density lipoprotein, and cholesterol. Mayo Clin Proc 63: 1012-1021, 1988.
11. Loichot C, Bentue-Ferrer D, Bernard N, et al. Cyclosporine monitoring in renal transplant recipients with induction therapy: C2 levels in patients monitored on C0. Fundam Clin Pharmacol 20:91-96, 2006.
12. Stenvinkel P, Alvestrand A, Angelin B, Eriksson M. LDLapheresis in patients with nephrotic syndrome: effects on serum albumin and urinary albumin excretion. Euro Jour of Cli Invest 30: 866-870, 2000.
13. Ideura T, Hora K, Kaneko Y, et al. Effect of low-density lipoprotein-apheresis on nephrotic syndrome due to membranous nephropathy in renal allograft: a case report. Transplant Proc 32:223-226, 2000.
14. Muso E, Mune M, Yorioka N, et al. Beneficial effect of lowdensity lipoprotein apheresis (LDL-A) on refractory nephrotic syndrome (NS) due to focal glomerulosclerosis (FGS). Clin Nephrol 67: 341-344, 2007.
15. Ueda S, Sugimoto K, Yanagida H, et al. Low-density lipoprotein adsorption therapy can restore drug sensitivity for immunosuppressants via inhibitory effects upon MDR-1 gene expression. Ther Apher Dial 15: 499-503, 2011.